Potassium binder lets heart patients get full drug benefits

NCT ID NCT05004363

Completed Disease control Sponsor: St George's, University of London Source: ClinicalTrials.gov ↗

First seen Apr 30, 2026 · Last updated Jun 17, 2026 · Updated 7 times

Summary

This study tested whether a drug called Lokelma (SZC) can help people with both chronic kidney disease and heart failure safely reach higher doses of life-saving heart medications (RAAS inhibitors) without dangerous potassium spikes. 112 adults with stable kidney disease and heart failure took either Lokelma or a placebo while doctors gradually increased their heart medication doses. The goal was to see if Lokelma allowed more patients to reach the maximum recommended heart drug dose while keeping potassium levels safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

St Georges, University of London

London, United Kingdom

Conditions

The condition(s) this trial relates to.

acute kidney injury chronic kidney disease chronic renal failure syndrome Hyperkalemia pseudohypoaldosteronism pseudohypoaldosteronism type 2 systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACE INHIBITOR INDUCED HYPERKALAEMIA CHRONIC KIDNEY DISEASES HEART FAILURE WITH REDUCED EJECTION FRACTION HYPERKALEMIA MINERALOCORTICOID RESISTANT HYPERKALEMIA